Hong Kong-listed CanSino Biologics opens down nearly 15%
2026-11-16 09:27:24
According to CoinMeta, Hong Kong-listed CanSino Biologics (09926.HK) opened down nearly 15%. On the news front, CanSino Biologics' overseas partner Summit Therapeutics announced that its application for the listing of Yivoxi has not been approved by the US Food and Drug Administration (FDA).
Bullish 0
Bearish 0
Source:Jin10 Data
This content is for market information only and does not constitute investment advice.